KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $4.2 billion.

  • Pfizer's Cost of Revenue fell 2072.96% to $4.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 billion, marking a year-over-year decrease of 1767.24%. This contributed to the annual value of $17.9 billion for FY2024, which is 2846.44% down from last year.
  • Latest data reveals that Pfizer reported Cost of Revenue of $4.2 billion as of Q3 2025, which was down 2072.96% from $3.8 billion recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Cost of Revenue peaked at $10.0 billion during Q2 2022, and registered a low of $2.8 billion during Q1 2025.
  • In the last 5 years, Pfizer's Cost of Revenue had a median value of $5.1 billion in 2023 and averaged $5.8 billion.
  • Per our database at Business Quant, Pfizer's Cost of Revenue surged by 39486.8% in 2021 and then tumbled by 6256.94% in 2023.
  • Pfizer's Cost of Revenue (Quarter) stood at $9.9 billion in 2021, then plummeted by 38.95% to $6.1 billion in 2022, then increased by 24.74% to $7.6 billion in 2023, then tumbled by 30.41% to $5.3 billion in 2024, then decreased by 20.73% to $4.2 billion in 2025.
  • Its last three reported values are $4.2 billion in Q3 2025, $3.8 billion for Q2 2025, and $2.8 billion during Q1 2025.